Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
Business Wire•29/10/2026•08:00 ET
0
Key Highlights
- ➤Total net product revenues $1,292M, up 52% year over year
- ➤AMVUTTRA revenues $1,130M, up 65% year over year
- ➤Total TTR revenues $1,150M, up 59% year over year
- ➤TRITON-CM enrollment target expanded from 1,750 to approximately 2,250 patients
- ➤2026 financial guidance reiterated, including total net product revenues of $4.7B-$5.1B
Expert Statements
Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
“Our third quarter results reflect the continued growth of our TTR franchise and advancement of key programs with the potential for transformative patient impact.”
Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
“As we continue through the final months of the year and plan for 2027, we remain laser focused on leveraging our commercial investments to expand the prescriber base, support access, and bring AMVUTTRA to more patients with ATTR amyloidosis.”
Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
“In line with our goal to build durable leadership in TTR, the expanded enrollment target for TRITON-CM we are announcing today further positions nucresiran for success and strengthens our long-term position.”
Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
“Lastly, we believe the positive initial data for brezosiran in Huntington's disease both support a pathway to initiating a pivotal study in 2027 and reflect the potential of our RNAi platform to create meaningful value beyond our current portfolio.”
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
− Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million (59% Growth Compared with Q3 2025) –
Get started
Create a free account to read the full story.